RISEDRONATE S.K.

Χώρα: Ισραήλ

Γλώσσα: Αγγλικά

Πηγή: Ministry of Health

Αγόρασέ το τώρα

Δραστική ουσία:

RISEDRONIC ACID AS SODIUM HEMIPENTAHYDRATE

Διαθέσιμο από:

K.S.KIM INTERNATIONAL (SK- PHARMA) LTD., ISRAEL

Φαρμακολογική κατηγορία (ATC):

M05BA07

Φαρμακοτεχνική μορφή:

TABLETS

Σύνθεση:

RISEDRONIC ACID AS SODIUM HEMIPENTAHYDRATE 150 MG

Οδός χορήγησης:

PER OS

Τρόπος διάθεσης:

Required

Κατασκευάζεται από:

PHARMSCIENCE INC., CANADA

Θεραπευτική περιοχή:

RISEDRONIC ACID

Θεραπευτικές ενδείξεις:

Treatment of postmenopausal osteoporosis. Prevention of postmenopausal osteoporosis.

Ημερομηνία της άδειας:

2022-10-31

Φύλλο οδηγιών χρήσης

                                PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’
REGULATIONS
(PREPARATIONS( - 1986
The medicine is dispensed with a doctor’s prescription only.
RISEDRONATE S.K.
Tablets
Composition:
Each
Risedronate S.K.
tablet contains: Risedronate sodium 150 mg
For the list of inactive and allergenic ingredients in the
preparation, see section 2 “Important
information regarding some of the ingredients of the medicine” and
section 6 “Further
information”.
Read the leaflet carefully in its entirety before using the medicine.
This leaflet contains
concise information about the medicine. If you have further questions,
refer to the doctor or
pharmacist.
This medicine has been prescribed to treat your ailment. Do not pass
it on to others. It may
harm them even if it seems to you that their medical condition is
similar.
This medicine is usually not intended for children or adolescents
below 18 years of age.
1.
WHAT IS THE MEDICINE INTENDED FOR?
This medicine is intended for the treatment and prevention of
osteoporosis in postmenopausal
women. Therapeutic group: This medicine belongs to the therapeutic
group of
bisphosphonates.
2. BEFORE USING THE MEDICINE
Do not use the medicine if:
•
you are sensitive (allergic) to the active ingredient or to any of the
additional ingredients
contained in the medicine - see also section 6 “Further
Information”.
•
you have certain esophagus problems.
•
you are unable to remain in an upright position (sitting or standing)
for at least 30
minutes after taking the medicine.
•
you are in a state of hypocalcemia (low levels of blood calcium)
Special warnings regarding use of the medicine
Before treatment with
Risedronate S.K.
, inform the doctor if:
•
you are suffering from swallowing problems.
•
you are suffering from digestive problems.
•
you have low blood calcium levels. In this condition, the doctor may
prescribe for you
calcium and vitamin D supplements during the course of treatment with
Risedronate
S.K.
.
•
you plan to have dental surgery or a tooth extra
                                
                                Διαβάστε το πλήρες έγγραφο
                                
                            

Έγγραφα σε άλλες γλώσσες

Φύλλο οδηγιών χρήσης Φύλλο οδηγιών χρήσης Αραβικά 27-12-2023
Φύλλο οδηγιών χρήσης Φύλλο οδηγιών χρήσης Εβραϊκά 16-11-2023

Αναζήτηση ειδοποιήσεων που σχετίζονται με αυτό το προϊόν

Προβολή ιστορικού εγγράφων